Negotiable
The date of payment from buyers deliver within days
Zhejiang
Long-term effective
2020-02-06 19:20
278
Company Profile
Hangzhou Jeci Biochem Technology Co .,Ltd.By certification [File Integrity]
Contact: jiexi(Mr.)
Email:
Telephone:
Phone:
Area: Zhejiang
Address: Zhejiang
Website: http://www.jecibiochem.com/ http://jiexi.imd-hk.com/
Pitavastatin calcium Basic information
Product Name: |
Pitavastatin calcium |
Synonyms: |
Pitavastatin Calcuim;Pitavastatin calcium, >=98.5%;Pitavastatin (calcium salt);monocalciumbis[(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-Fluorophenyl)-3-Quinolyl)-3,5-Dihydroxy-6-heptenoate](+)a- Phenethylamine Sal;Pitavastatin Calciu;Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoat;PITAVASTATIN CALCIUM 3S-5R ISOMER IMP;6-heptenoicacid,7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydro |
CAS: |
147526-32-7 |
MF: |
C50H46CaF2N2O8 |
MW: |
880.98 |
EINECS: |
807-641-2 |
Pitavastatin calcium Chemical Properties
alpha |
D20 +23.1° (c = 1.00 in acetonitrile/water) |
Pitavastatin calcium Usage And Synthesis
Statin lipid-lowering drugs |
Pitavastatin calcium is jointly developed by two companies Nissan Chemical and Kowa Co.it is the first total synthesis HMG-CoA reductase inhibitor, it belongs to statin drugs ,it reduces the ability of the liver to manufacture cholesterol mainly through inhibition of some liver enzymes called HMGCo-A reductase , thus it improves the elevated blood cholesterol levels, it is primarily used for the treatment of hypercholesterolemia and familial hypercholesterolemia patients,its lipid-lowering effect is very good, it is the most potent lipid-lowering drug so far. |
Description |
Pitavastatin, launched for the treatment of hypercholesterolemia, belongs to the family of second-generation statins, also referred to as superstatins due to their improved efficacy as cholesterol lowering agents. Like other statins, pitavastatin reduces plasma cholesterol levels by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis in the liver. It is a more potent inhibitor of HMG-CoA reductase than the previously marketed statins and has the potential benefit of not undergoing significant metabolism by CYP3A4. Pitavastatin is synthesized in a multi-step sequence, including the key step of introducing the dihydroxyheptenoate side chain by cross-coupling of a 3-iodoquinoline intermediate with an alkenylborane reagent. Unlike rosuvastatin, pitavastatin has a high oral bioavailability (~80%). Plasma protein binding is also high for pitavastatin (>95%), and regardless of the dosing, the highest tissue levels are found in the liver, its target organ. After oral administration, the peak plasma concentration is reached at ,0.8 h and the mean elimination half-life is ~11 h. Pitavastatin is only minimally metabolized, mainly by CYP2C8 and CYP2C9, and the predominant route of elimination of the parent drug and its metabolites is by means of bile excretion followed by elimination in the feces. In clinical studies, oral doses of 2–4 mg/day of pitavastatin produced dose-dependent reduction in LDL-cholesterol levels by 40–48% from baseline in patients with heterozygous familial hypercholesterolemia. In a 12-week double-blind comparative study, pitavastatin (2 mg/day) was more effective than pravastatin (10 mg/day) in reducing LDL-cholesterol levels (38 and 18%, respectively); however, both agents produced similar increases in HDL-cholesterol (~9%). The drug was well tolerated and the adverse reactions were mild and transient. |
Chemical Properties |
White to Off-White Powder |
http://www.jecibiochem.com/